People with FSHD, ages 16 to 70, enrolled in this Phase 1/2 FORTITUDE trial cohort will aid biomarker data to support early approval request.

Modalis Therapeutics is seeking to make MDL-101 the first treatment for people with LAMA2-related congenital muscular ...

The progression of myotonic dystrophy type 1 (DM1) differs according to sex and age at symptom onset, a four-year follow-up ...

Columnist Shalom Lim celebrates a new beginning in a new job, where his mission to serve fellow patients with muscular ...

Columnist Betty Vertin, the mother of three boys with DMD, has the experience and self-assurance to know she can do hard things.

Idlewild, which is near Ligonier, Pennsylvania, is an old-style amusement park that’s been around since the days when the gentry from Pittsburgh took the train to their summer homes in the foothills ...

CureDuchenne is partnering with Blizzard Entertainment, maker of the massively multiplayer online role-playing game World of Warcraft, on a fundraiser to help advance research into new treatments for ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...

Usually a DIY project solves a family problem, but columnist Betty Vertin now wonders if her creative efforts contributed to an injury.